Consumer medicine information

1. Why am I using Levetiracetam-WGR?

Levetiracetam-WGR contains the active ingredient levetiracetam. Levetiracetam-WGR is used to control epilepsy.
For more information, see Section 1. Why am I using Levetiracetam-WGR? in the full CMI.

2. What should I know before I use Levetiracetam-WGR?

Do not use if you have ever had an allergic reaction to levetiracetam or any of the ingredients listed at the end of the CMI.
Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.
For more information, see Section 2. What should I know before I use Levetiracetam-WGR? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with Levetiracetam-WGR and affect how it works.
A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use Levetiracetam-WGR?

• For patients 12 years of age and older, the dosage is generally between 1000 mg and 3000 mg each day, taken in two doses.

• For children 4 to 11 years of age the doctor will calculate the dosage based on the child's weight and tell you how much to give. The medicine is to be given twice daily.

5. What should I know while using Levetiracetam-WGR?

6. Are there any side effects?

Common side effects include: dizziness, feeling weak, headache, common cold, upset stomach, diarrhoea, feeling tired, drowsy or sleepy.
Serious side effects include: mood changes such as depression, nervousness, aggression, anger, anxiety, confusion, hallucination, irritability, feelings of depression, upper respiratory tract infections, weight loss.
Very serious side effects include: thoughts of harming yourself, more frequent or more severe seizures, shortness of breath, wheezing or difficulty breathing, swelling, blistering or peeling skin around the face, lips, mouth, throat, tongue, genitals or other parts of the body, rash, itching or hives on the skin.
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

Notes

Distributed by Wagner Pharmaceuticals Pty Ltd

1 Name of Medicine

Levetiracetam.

2 Qualitative and Quantitative Composition

Levetiracetam-WGR 250 mg film-coated tablets. Each film coated tablet contains 250 mg levetiracetam.
Levetiracetam-WGR 500 mg film-coated tablets. Each film-coated tablet contains 500 mg levetiracetam.
Levetiracetam-WGR 1000 mg film-coated tablet. Each film-coated tablet contains 1000 mg levetiracetam.
For the full list of excipients, see Section 6.1.

3 Pharmaceutical Form

Film-coated tablet.
Levetiracetam-WGR 250 mg film-coated tablets. Light blue, capsule shaped, biconvex film coated tablets plain on both sides.
Levetiracetam-WGR 500 mg film-coated tablets. Yellow, capsule shaped, biconvex film coated tablets plain on both sides.
Levetiracetam-WGR 1000 mg film-coated tablets. White, capsule shaped, biconvex film coated tablets plain on both sides.

4 Clinical Particulars

4.9 Overdose

The highest known dose of levetiracetam received in the clinical development program was 6000 mg/day. Other than drowsiness, there were no adverse events in the few known cases of overdose in clinical trials. Cases of somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses in postmarketing use.
There is no specific antidote for levetiracetam. Treatment for an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60% for levetiracetam and 74% for the major metabolite (ucb L057).
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. Levetiracetam was negative in gene mutation assays (bacterial, Chinese hamster ovary/ HGPRT locus) and in assays for chromosomal damage in vitro and in vivo (Chinese hamster ovary cells, mouse micronucleus assay). The hydrolysis product and major human metabolite (ucb L057) was not mutagenic in bacterial reverse mutation assays or the in vitro mouse lymphoma assay.
Carcinogenicity. There was no evidence of carcinogenicity following administration of levetiracetam in the diet to rats or orally to mice for 104 weeks, associated with respective systemic exposures (plasma AUC) up to 4-fold and 8-fold that in humans at the maximal recommended clinical dose of 3000 mg/day.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Levetiracetam is a white to off-white powder with a faint odour and a bitter taste. It is very soluble in water (104 g/100 mL). It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane.
Chemical name: (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide.
Chemical structure.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSLEVETI.gif Molecular formula: C₈H₁₄N₂O₂.
CAS number. 102767-28-2.

7 Medicine Schedule (Poisons Standard)

Schedule 4 (S4) - Prescription only medicine.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/LEVWGRST.gif